Biophytis (BPTSY)
OTHER OTC:BPTSY
Top Page
Biophytis
(OTC:BPTSY)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.80
▲(7.84% Upside)
Action:UpgradedDate:12/30/25
The score is primarily held down by weak financial performance (no revenue, ongoing cash burn, and negative equity), reinforced by bearish technicals with the stock trading below major moving averages. Valuation is also constrained by negative earnings and no dividend support, with only a minor offset from oversold momentum readings.
Positive Factors
Focused clinical-stage pipeline
Biophytis is a clinical-stage biotech focused on age-related diseases with a clear lead program (Sarconeos/BIO101). A focused R&D portfolio concentrates resources on a single high-value indication, preserving capital and management attention to advance trials and partner/licence outcomes.
Negative Factors
No revenue / no commercial product
Biophytis has no product revenues and remains pre-commercial, meaning its long-term viability depends on clinical/regulatory success or partnerships. This structural absence of recurring revenue increases execution risk and prolongs reliance on external funding to sustain operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused clinical-stage pipeline
Biophytis is a clinical-stage biotech focused on age-related diseases with a clear lead program (Sarconeos/BIO101). A focused R&D portfolio concentrates resources on a single high-value indication, preserving capital and management attention to advance trials and partner/licence outcomes.
Read all positive factors
Biophytis (BPTSY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.90M
Dividend YieldN/A
Average Volume (3M)52.00
Price to Earnings (P/E)―
Beta (1Y)0.65
Revenue GrowthN/A
EPS Growth84.55%
CountryUS
Employees22
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding9,165,092
10 Day Avg. Volume88
30 Day Avg. Volume52
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.60
Price to Sales (P/S)0.00
P/FCF Ratio-1.79
Enterprise Value/Market Cap3.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-30.87
Enterprise Value/Ebitda-0.99
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-13.26
Revenue Forecast (FY)$2.36M
Biophytis Business Overview & Revenue Model
Company Description
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and ...
How the Company Makes Money
Biophytis generates revenue through the development and potential commercialization of its drug candidates. The company's revenue model primarily focuses on licensing agreements, partnerships, and collaborations with other pharmaceutical companies...
Biophytis Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
14
Very Negative
| Breakdown | Jun 2025 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -803.00K | -484.00K | -311.00K | -280.00K |
| EBITDA | -8.26M | -13.80M | -22.79M | -26.50M | -13.66M |
| Net Income | -10.38M | -17.03M | -24.22M | -31.16M | -25.52M |
Balance Sheet | |||||
| Total Assets | 6.90M | 11.96M | 21.99M | 36.26M | 27.21M |
| Cash, Cash Equivalents and Short-Term Investments | 78.00K | 5.93M | 11.05M | 25.16M | 18.77M |
| Total Debt | 9.84M | 8.27M | 12.13M | 16.65M | 9.10M |
| Total Liabilities | 16.60M | 15.85M | 23.90M | 30.56M | 20.38M |
| Stockholders Equity | -9.67M | -3.86M | -1.88M | 5.83M | 2.30M |
Cash Flow | |||||
| Free Cash Flow | -8.64M | -13.09M | -19.13M | -24.14M | -10.08M |
| Operating Cash Flow | -8.64M | -12.87M | -18.99M | -23.80M | -9.86M |
| Investing Cash Flow | 10.00K | 370.00K | -17.00K | 12.16M | -12.71M |
| Financing Cash Flow | 3.14M | 7.03M | 6.13M | 29.71M | 21.95M |
Biophytis Technical Analysis
Negative
0.74
Price Trends
0.52
Negative
0.68
Negative
1.22
Negative
Market Momentum
-0.07
Negative
21.86
Positive
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BPTSY, the sentiment is Negative. The current price of 0.74 is above the 20-day moving average (MA) of 0.33, above the 50-day MA of 0.52, and below the 200-day MA of 1.22, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 21.86 is Positive, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BPTSY.
Biophytis Risk Analysis
Biophytis disclosed 71 risk factors in its most recent earnings report. Biophytis reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
Our drug candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval or authorization, limit the commercial profile of an approved or authorized label, or result in significant negative consequences following marketing approval or authorization, if any. Q4, 2023
2.
A resurgence of COVID-19 (or emergence of new vaccine resistant strains), pandemic, endemic, or emergence of other infectious disease, may limit our ability or the investigators' ability to find and retain medical staffs that are needed to conduct the clinical studies. Q4, 2023
Biophytis Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | $1.90M | -0.18 | ― | ― | ― | 84.55% | |
| ― | $2.60M | -0.17 | -168.95% | ― | ― | 90.27% | |
42 Neutral | $1.89M | ― | -82.17% | ― | -3.27% | 51.83% | |
| ― | $810.04K | -1.82 | -263.57% | ― | -34.58% | 96.41% |
* Healthcare Sector Average
BPTSY
Biophytis
0.30
-1.74
-85.46%
OGEN
Oragenics
0.60
-5.10
-89.49%
INM
InMed Pharmaceuticals
0.65
-1.78
-73.36%
KTTA
Pasithea Therapeutics Corp
0.77
-0.32
-29.72%
SPRC
SciSparc Ltd.
3.42
-48.65
-93.43%
ONCO
Onconetix
1.13
-25.90
-95.82%
Biophytis Corporate Events
Biophytis Announces Approval of Resolutions at General Meeting
Nov 14, 2025
On November 13, 2025, Biophytis announced that all resolutions proposed during their Combined General Meeting were approved, including the financial statements for the fiscal year 2024. This approval, achieved with a shareholder quorum of nearly 3...
Biophytis Releases Interim Financial Report for H1 2025
Oct 31, 2025
On October 31, 2025, Biophytis S.A. released its Interim Financial Report for the first half of fiscal year 2025. This report provides insights into the company’s financial performance, including significant events, research and development ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.